Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER3-DXd plus osimertinib in EGFR-mutated advanced non-small cell lung cancer
jRCT2031200247Phase 1Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of patritumab deruxtecan and osimertinib in non-small cell lung cancer (NSCLC) (7 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety parameters and Objective response rate. Started Dec 2020; status: active, not recruiting.
02
Drugs
patritumab deruxtecanosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031200247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200247.